Clarification of the pathogenesis of myeloproliferative neoplasms based on the identification of genetic factors in familial cases
Project/Area Number |
17H04211
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Juntendo University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
森下 総司 順天堂大学, 医学部, 助教 (10635866)
荒木 真理人 順天堂大学, 医学(系)研究科(研究院), 先任准教授 (80613843)
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2019: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2018: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
Keywords | 骨髄増殖性腫瘍 / iPS細胞 / JAK2V617F変異 / CRISPR/Cas9 / JAK2 / iPS / ゲノム編集 / 網羅的遺伝子解析 / 家族性骨髄増殖性腫瘍 / ドライバー遺伝子 / 骨髄線維症 / 急性白血病 / 遺伝子 / 癌 / 細胞 / ゲノム |
Outline of Final Research Achievements |
Philadelphia negative myeloproliferative neoplasms (MPN) are clonal disorders characterized by an overproduction of terminally differentiated hematopoietic cells. A majority of patients with MPN harbor JAK2V617F mutation, which is though as a driver gene mutation. Despite of several studies using mouse models and cell lines that link the JAK2V617F mutation and MPN, it was ambiguous whether JAK2V617F mutation alone was sufficient for the presentation of MPN phenotypes such as overproduction of terminally differentiated hematopoietic cells. In this study, we employed iPS cells derived from a healthy donor, introduced JAK2V617F mutation into these iPS cells, and demonstrated that the JAK2V617F alone was sufficient to induce MPN phenotypes in vitro.
|
Academic Significance and Societal Importance of the Research Achievements |
健常人から作ったiPS細胞にJAK2V617F変異を導入したところ、骨髄増殖性腫瘍患者でみられる造血能の亢進を、iPS細胞でも観察することができ、このiPS細胞を用いてJAK2V617F遺伝子の役割を解析することに成功した。このことから、今後はこのiPS細胞を用いて、新たな治療法の開発や病態解明がすすめられることから、その学術的意義、社会的意義は大きいと考える。
|
Report
(4 results)
Research Products
(60 results)
-
-
-
-
[Journal Article] Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations2018
Author(s)
Hiraku Takei, Yoko Edahiro, Shuichi Mano, Nami Masubuchi, Yoshihsa Mizukami, Misa Imai, Soji Morishita, Kyohei Misawa, Tomonori Ochiai, Satoshi Tsuneda, Hiroshi Endo, Sou Nakamura, Koji Eto, Akimichi Ohsaka, Marito Araki, Norio Komatsu
-
Journal Title
British Journal of Haematology
Volume: 印刷中
Issue: 6
Pages: 791-802
DOI
Related Report
Peer Reviewed
-
[Journal Article] The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.2018
Author(s)
Ochiai T, Yasuda H, Araki M, Misawa K, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N.
-
Journal Title
Eur J Haematol
Volume: 印刷中
Issue: 6
Pages: 544-549
DOI
Related Report
Peer Reviewed
-
-
[Journal Article] Multiple Placental Infarcts in a Pregnant Woman with Essential Thrombocythemia.2018
Author(s)
Edahiro Y, Ando J, Suzuki T, Fukumura Y, Masuda A, Sakayori S, Takeda J, Maruyama Y, Makino S, Itakura A, Komatsu N.
-
Journal Title
Internal Medicine.
Volume: 57
Pages: 3647-3650
NAID
Related Report
Peer Reviewed
-
[Journal Article] Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.2018
Author(s)
Oritani K, Ohishi K, Okamoto S, Kirito K, Komatsu N, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Okada H, Amagasaki T, Wakase S, Shimozuma K, Akashi K.
-
Journal Title
Curr Med Res Opin.
Volume: 34
Pages: 531-537
Related Report
Peer Reviewed
-
[Journal Article] Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.2018
Author(s)
Kirito K, Okamoto S, Ohishi K, Tauchi T, Handa H, Saito S, Takenaka K, Shimoda K, Oritani K, Akashi K, Okada H, Amagasaki T, Suzuki K, Yonezu T, Komatsu N
-
Journal Title
Int J Hematol
Volume: 107(1)
Issue: 1
Pages: 92-97
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Hmga2 collaborates with JAK2 V617F in the development of myeloproliferative neoplasms2017
Author(s)
Ueda K, Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima-Nakamura A, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama Aand Takeishi Y.
-
Journal Title
Blood Advances
Volume: 1
Issue: 15
Pages: 1001-1015
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] The 2016 WHO diagnostic criteria for polycythemia vera renders an accurate diagnosis to a broader range of patients including masked polycythemia vera: Comparison with the 2008 WHO diagnostic criteria.2017
Author(s)
Misawa K, Yasuda H, Araki M, Ochiai T, Morishita S, Nudejima M, Hironaka Y, Shirane S, Edahiro Y, Gotoh A, Ohsaka A, Komatsu N.
-
Journal Title
Am J Hematol
Volume: 92
Issue: 7
DOI
Related Report
Peer Reviewed
-
[Journal Article] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.2017
Author(s)
Komatsu N, Kirito K, Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, Takahashi N, Okada H, Amagasaki T, Yonezu T, Akashi K.
-
Journal Title
Int J Hematol.
Volume: 105
Pages: 309-317
Related Report
Peer Reviewed
-
[Journal Article] The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.2017
Author(s)
Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA.
-
Journal Title
Ann Hematol.
Volume: 96
Issue: 10
Pages: 1653-1665
DOI
Related Report
Peer Reviewed / Open Access
-
[Presentation] JAK2 V617Fのコピー数はサイトカイン受容体の活性化に重要である.2019
Author(s)
北澤爽汰, 荒木真理人, 塩入香穂, 森下総司, 増渕菜弥, 馬場照美, 山本誠司, 堀内祥行, 今井美沙, 大坂顯通, 小松則夫.
Organizer
第81回日本血液学会学術集会
Related Report
-
-
-
[Presentation] JAK2アレルバーデンの高い患者は血小板コントロールが良好でもvWF活性低値のリスクが高い.2019
Author(s)
飯塚和秀, 入山規良, 森下総司, 三浦勝浩, 飯塚芳一, 西崎祐史, 柳澤尚武, 安藤純, 内野慶人, 高橋宏通, 中川優, 濱田高志, 八田善弘, 中山智祥, 武井正美, 小松則夫.
Organizer
第81回日本血液学会学術集会
Related Report
-
-
[Presentation] 非ドライバー変異と予後予測システムDIPSS/DIPSS-plus.2019
Author(s)
森下総司, 落合友則, 三澤恭平, 大佐賀智, 稲野資明, 福田泰隆, 黒川安満, 枝廣陽子, 橳島麻衣, 緑川直子, 荒木真理人, 大坂顯通, 小松則夫.
Organizer
第81回日本血液学会学術集会
Related Report
-
-
[Presentation] 真性多血症患者由来iPS細胞におけるJAK2 V617F変異の修正.2019
Author(s)
枝廣陽子, 劉暢, 荒木真理人, 橳島麻衣, 森下総司, 今井美沙, 増渕菜弥, 水上喜久, 眞野修一, 竹井拓, 大坂顯通, 小松則夫.
Organizer
第81回日本血液学会学術集会
Related Report
-
-
[Presentation] 真正トリプルネガティブ本態性血小板血症における臨床的・分子生物学的特異性.2019
Author(s)
稲野資明, 荒木真理人, 森下総司, 落合友則, 三澤恭平, 福田泰隆, 緑川直子, 橳島麻衣, 伊藤雅文, 大佐賀智, 枝廣陽子, 今井美沙, 田口鉄平, 奥田真帆, 大坂顯通, 小松則夫.
Organizer
第81回日本血液学会学術集会
Related Report
-
-
-
-
-
[Presentation] Boarding on the secretary pathway is required for the oncogenic property of mutant calreticulin.2018
Author(s)
Araki M, Masubuchi N, Hayashi E, Yang Y, Imai M, Kihara Y, Mizukami Y, Hironaka Y, Edahiro Y, Ohsaka A, Komatsu N.
Organizer
23rd Congress of the European Hematology Association
Related Report
Int'l Joint Research
-
-
[Presentation] 細胞減少療法はPMF患者における腎機能の悪化を防止する.2018
Author(s)
福田泰隆, 荒木真理人, 山本紘司, 森下総司, 稲野資明, 三澤恭平, 落合友則, 枝廣陽子, 今井美沙, 後藤明彦, 大坂顯通, 小松則夫.
Organizer
第80回日本血液学会学術集会
Related Report
-
-
-
[Presentation] 変異型 CALRの多量体化は MPLとの結合と活性化に必須である.2018
Author(s)
荒木真理人, 楊印杰, 今井美沙, 水上喜久, 木原慶彦, 角南義孝, 増渕菜弥, 枝廣陽子, 弘中由美, 大佐賀智, 大坂顯通, 小松則夫.
Organizer
第80回日本血液学会学術集会
Related Report
-
[Presentation] トリプルネガティブ本態性血小板血症症例の臨床像と遺伝子変異.2018
Author(s)
稲野資明, 荒木真理人, 福田泰隆, 森下総司, 落合友則, 三澤恭平, 伊藤雅文, 山本紘司, 楊印杰, 田口鉄平, 枝廣陽子, 今井美沙, 後藤明彦, 大坂顯通, 小松則夫.
Organizer
第80回日本血液学会学術集会
Related Report
-
-
[Presentation] Establishment of an in vitro model for the skewed megakaryopoiesis by calreticulin mutation in human cells.2017
Author(s)
Takei H, Mano S, Masubuchi N, Mizukami Y, Morishita S, Imai M, Edahiro Y, Hironaka Y, Nudejima M, Tsuneda S, Endo H, Nakamura S, Eto K, Ohsaka A, Araki M, Komatsu N.
Organizer
22nd Congress of the European Hematology Association
Related Report
Int'l Joint Research
-
[Presentation] Localization of Mutant Calreticulin in the Golgi Apparatus Is Required for Its Oncogenic Capacity.2017
Author(s)
Masubuchi N, Araki M, Hayashi E, Yang Y, Imai M, Kihara Y, Mizukami Y, Hironaka Y, Takei H, Edahiro Y, Ohsaka A, Komatsu N.
Organizer
59th Annual Meeting of the American Society of Hematology and Exposition
Related Report
Int'l Joint Research
-
[Presentation] 家族性骨髄増殖性腫瘍患者からの iPS細胞株の樹立.2017
Author(s)
眞野修一, 竹井拓, 森下総司, 水上喜久, 増渕菜弥, 弘中由美, 橳島麻衣, 常田聡, 大坂顯通, 荒木真理人, 小松則夫.
Organizer
第79回日本血液学会学術集会
Related Report
-
[Presentation] 骨髄増殖性腫瘍に見出される変異型 CALR 蛋白質の細胞内局在.2017
Author(s)
林英里奈, 荒木真理人, 増渕菜弥, 水上喜久, 楊印杰, 今井美沙, 弘中由美, 竹井拓, 木原慶彦, 枝廣陽子, 大坂顯通, 小松則夫.
Organizer
第79回日本血液学会学術集会
Related Report
-
-
[Presentation] 変異型 CALR タンパク質の発現を制御するメカニズム.2017
Author(s)
木原慶彦, 荒木真理人, 楊印杰, 今井美沙, 増渕菜弥, 水上喜久, 弘中由美, 竹井拓, 枝廣陽子, 大坂顯通, 小松則夫.
Organizer
第79回日本血液学会学術集会
Related Report
-
-
[Presentation] カルレチキュリン変異を有する血球前駆細胞は巨核球への分化偏向性を有する.2017
Author(s)
竹井拓, 眞野修一, 増渕菜弥, 水上喜久, 今井美沙, 森下総司, 枝廣陽子, 弘中由美, 橳島麻衣, 常田聡, 遠藤大, 中村壮, 江藤浩之, 大坂顯通, 荒木真理人, 小松則夫.
Organizer
2017年度生命科学系学会合同年次大会
Related Report
-
[Presentation] 変異型 CALR による巨核球分化偏向性は GATA2 の発現亢進と相関している.2017
Author(s)
竹井拓, 眞野修一, 増渕菜弥, 水上喜久, 今井美沙, 森下総司, 枝廣陽子, 弘中由美, 橳島麻衣, 遠藤大, 中村壮, 江藤浩之, 大坂顯通, 荒木真理人, 小松則夫.
Organizer
第79回日本血液学会学術総会
Related Report
-
-
-
[Presentation] Engagement of mutant calreticulin and MPL in a cellular compartment is required for MPL activation.2017
Author(s)
Masubuchi N, Araki M, Hayashi E, Yang Y, Imai M, Mizukami Y, Hironaka Y, Takei H, Morishita S, Kihara Y, Edahiro Y, Ohsaka A, Komatsu N.
Organizer
第79回日本血液学会学術集会
Related Report
-
-
-
-
-
-
-
-
-
-
-